> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA, MHRA Launch Liaison Program for Regulatory Cooperation
- URL: https://www.fdaweb.com/fda-mhra-launch-liaison-program-for-regulatory-cooperation/
- Published: 2026-06-15T12:00:00.000Z
- Updated: 2026-09-14T13:41:11.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5161312

FDA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have unveiled a new liaison program designed to strengthen collaboration between the two regulators on medicines, medical devices and emerging technologies, including artificial intelligence. The initiative, announced Monday at the DIA Global Annual Meeting in Philadelphia, will establish reciprocal liaison officer positions within each agency to facilitate closer day-to-day engagement and information sharing.

FDA deputy commissioner **Grace Graham** and MHRA chief executive **Lawrence Tallon** said the program is intended to enhance scientific exchange, improve regulatory coordination and help both agencies respond more effectively to rapidly evolving technologies and public health challenges. The move formalizes an already close relationship between the agencies and reflects growing efforts by regulators to coordinate oversight of increasingly globalized product development programs.

Graham emphasized the potential benefits for product developers and patients, particularly as regulators confront increasingly complex scientific and technological issues. "American patients and innovators benefit when regulators collaborate, as aligning on regulatory science can speed access to medical products and reduce time to markets both here and in the UK," she said. Graham added that the program is expected to improve institutional knowledge within both agencies and strengthen oversight of drugs, biologics and medical devices while supporting efforts to secure pharmaceutical supply chains and maintain clinical research standards.

"By creating dedicated liaison roles, we are taking our collaboration to a new level, improving how we share expertise, align on regulatory science and technology, and respond to the pace of innovation," Tallon said. He said greater regulatory alignment could help reduce barriers for companies seeking to bring products to market in both countries. "This will help product developers cross the Atlantic, in both directions, because our regulatory decisions will become more closely aligned, reducing friction to market from the UK to the US and vice versa," he added.

The agencies stressed that the arrangement will not affect their regulatory independence. While the liaison officers will facilitate coordination and information exchange, both regulators will continue to make independent approval and enforcement decisions.

The announcement follows a commitment made earlier this year by the FDA and MHRA to expand cooperation on medical device regulation as part of a broader U.S.-UK pharmaceutical partnership.

AdvaMed president and CEO **Scott Whitaker** described the program as a model for regulatory collaboration, saying it could help reduce administrative burdens and keep pace with innovation in the medical technology sector.